[Executive functioning and evoked potentials P300 pre- and post- treatment in attention deficit hyperactivity
Patricia Roca1, Fernando Mulas, Rubén Gandia
1Instituto Valenciano de Neurologia Pediatrica (INVANEP), Artes Gráficas 23, Valencia, Spain. patricia.roca@invanep.com
Revista De Neurologia
|March 1, 2013
Summary
Attention deficit hyperactivity disorder (ADHD) treatments with atomoxetine and methylphenidate both improved executive functions and P300 evoked potentials in children. These objective measures are valuable for clinical practice and personalized treatment strategies.
Area of Science:
- Neuroscience
- Pediatrics
- Psychopharmacology
Context:
- Attention deficit hyperactivity disorder (ADHD) significantly impacts cognitive functions.
- Evoked potentials P300 and executive functions are established biomarkers for monitoring ADHD.
- Pharmacological interventions like atomoxetine and methylphenidate are common ADHD treatments.
Purpose:
- To compare the efficacy of atomoxetine versus methylphenidate in improving executive functions and P300 evoked potentials in children with ADHD.
- To analyze the correlation between P300 parameters and neuropsychological measures.
- To assess treatment effects over a one-year follow-up period.
Summary:
- This study analyzed neuropsychological profiles and P300 evoked potentials in two groups of children with ADHD, one treated with atomoxetine (n=22) and the other with methylphenidate (n=24).
- Both treatment groups showed significant global improvements in executive functions and P300 values after one year.
- Correlations between P300 and neuropsychological parameters were explored, alongside basal and follow-up value differences.
Impact:
- Executive functions and P300 evoked potentials serve as crucial indicators of underlying cognitive processing in ADHD.
- The findings underscore the clinical utility of these measures for patient monitoring.
- This research highlights the potential for developing personalized, objective variable-based ADHD treatment strategies.
